Molecular diagnostics and liquid biopsy approaches in diffuse midline glioma: an update and literature review

Purpose Diffuse midline gliomas (DMGs), H3 K27-altered, are aggressive childhood central nervous system tumors that remain almost uniformly fatal. Historically diagnosed radiographically as diffuse intrinsic pontine glioma (DIPG), these tumors are now defined by integrated anatomic and molecular criteria encompassing H3 K27-mutant, EZHIP-overexpressing, and EGFR-altered subtypes. Advances in tissue sampling have transformed understanding of their molecular landscape, but their eloquent location, the sampling bias inherent to stereotactic biopsy, and the impracticality of repeated tissue sampling have motivated interest in biofluid-based approaches. Liquid biopsy is being investigated as a complementary modality for molecular characterization, longitudinal monitoring, and detection of progression and resistance. Methods A narrative review of the literature was performed using PubMed/MEDLINE for articles published through 31 July 2026, supplemented by a ClinicalTrials.gov search performed on the same date. Eligible articles described liquid biopsy methodologies, biomarker substrates, or clinical applications in DMG or DIPG; a separate, explicitly labeled category of enabling or methodologically relevant studies performed on tissue or in other tumor types was retained. Results We summarize the WHO CNS5 molecular definition of DMG, the role and limitations of tissue-based diagnosis, the spectrum of liquid biopsy substrates and platforms with study-level performance data, and the incorporation of cerebrospinal fluid (CSF) sampling into interventional DMG trials. We distinguish exploratory biomarker collection from analytically or clinically validated testing, and we address CSF access, safety, selection bias, and turnaround time. Conclusions Liquid biopsy in DMG remains investigational. No application, whether molecular diagnosis, response monitoring, pseudoprogression adjudication, or treatment adaptation, is currently prospectively validated for clinical decision-making. Standardized, prospective, multi-institutional studies with predefined thresholds are required.

Authors

Publication Details

Journal
Child s Nervous System
Published
2026-11-20
DOI
https://doi.org/10.1007/s00381-026-07530-3
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Molecular diagnostics and liquid biopsy approaches in diffuse midline glioma: an update and literature review

Daphne D. Li, Sudarshawn N. Damodharan
Child s Nervous System
Glioma Diagnosis and Treatment
article

Molecular diagnostics and liquid biopsy approaches in diffuse midline glioma: an update and literature review

Daphne D. Li, Sudarshawn N. Damodharan
article en

Abstract

Purpose Diffuse midline gliomas (DMGs), H3 K27-altered, are aggressive childhood central nervous system tumors that remain almost uniformly fatal. Historically diagnosed radiographically as diffuse intrinsic pontine glioma (DIPG), these tumors are now defined by integrated anatomic and molecular criteria encompassing H3 K27-mutant, EZHIP-overexpressing, and EGFR-altered subtypes. Advances in tissue sampling have transformed understanding of their molecular landscape, but their eloquent location, the sampling bias inherent to stereotactic biopsy, and the impracticality of repeated tissue sampling have motivated interest in biofluid-based approaches. Liquid biopsy is being investigated as a complementary modality for molecular characterization, longitudinal monitoring, and detection of progression and resistance. Methods A narrative review of the literature was performed using PubMed/MEDLINE for articles published through 31 July 2026, supplemented by a ClinicalTrials.gov search performed on the same date. Eligible articles described liquid biopsy methodologies, biomarker substrates, or clinical applications in DMG or DIPG; a separate, explicitly labeled category of enabling or methodologically relevant studies performed on tissue or in other tumor types was retained. Results We summarize the WHO CNS5 molecular definition of DMG, the role and limitations of tissue-based diagnosis, the spectrum of liquid biopsy substrates and platforms with study-level performance data, and the incorporation of cerebrospinal fluid (CSF) sampling into interventional DMG trials. We distinguish exploratory biomarker collection from analytically or clinically validated testing, and we address CSF access, safety, selection bias, and turnaround time. Conclusions Liquid biopsy in DMG remains investigational. No application, whether molecular diagnosis, response monitoring, pseudoprogression adjudication, or treatment adaptation, is currently prospectively validated for clinical decision-making. Standardized, prospective, multi-institutional studies with predefined thresholds are required.

Child s Nervous SystemVol. 42(1)
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon